Trinity Biotech plc to Announce Second Quarter 2020 Financial Results

Conference Call Scheduled for August 25, 2020 at 11:00am EASTERN

Bray Co Wicklow, IRELAND

DUBLIN, Ireland, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the second quarter 2020 on Tuesday, August 25, 2020. The Company has scheduled a conference call for that same day, Tuesday, August 25, 2020 at 11:00am ET (4:00pm BST) to discuss the results of the quarter.

Interested parties can access the call by dialing:
 US Toll Free:1-844-861-5499
 International Toll:1-412-317-6581
 Ireland Toll:014311269
 Ireland Toll Free:1800932830
Please ask to be joined into the Trinity Biotech call.

A simultaneous webcast of the call can be accessed at:

A replay of the call can be accessed until September 1, 2020 by dialing:
 US Toll Free:1-877-344-7529
 International Toll:1-412-317-0088 
 Replay Code:10147281

To access the replay using an international dial-in number, please see the link below:

A webcast of the call will be available until August 25, 2021:

Replays will be available 1 hour after the end of the conference.

Forward-looking statements in this release are made pursuant to the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialisation and technological difficulties. In addition, there is uncertainty about the spread of the COVID19 virus and the impact it will have on the Company’s operations, the demand for Company’s products, global supply chains and economic activity in general. These and other risks and uncertainties are detailed in the Company’s Securities and Exchange Commission filings.

Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information please see the Company's website:

Kevin Tansley
Trinity Biotech plc